ALX ONCOLOGY HOLDINGS INC 8-K

What Happened

• ALX Oncology Holdings, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release dated May 8, 2026. The company filed a Current Report on Form 8-K (May 8, 2026) to furnish that press release; the release is included as Exhibit 99.1 to the 8-K. The report was signed by Chief Financial Officer Harish Shantharam.

Key Details

• Filing date: May 8, 2026.
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K includes the Inline XBRL cover page (Exhibit 104) and was signed by CFO Harish Shantharam.

Why It Matters

• This 8-K formally notifies investors that ALX Oncology has released its quarterly earnings and related financial information; investors should review the furnished press release (Exhibit 99.1) for revenue, earnings, cash position, and other quarterly metrics.
• Routine disclosure like this can contain material results or updates that may affect the stock price or investor decisions, so shareholders and analysts typically read the press release and any accompanying financial statements or slides for details on revenue, R&D spending, cash runway, and clinical program updates.